Marrow-ablative Consolidation Chemotherapy and Molecular Targeted Therapy Delivered in a Risk-adapted Manner for Newly Diagnosed Children with Choroid Plexus Carcinoma: A Work in Progress
Maxim Yankelevich, W. Zaky, L. Lafay-Cousin, Diana Osorio, Jenny K Adamski, U. Kordes, Jonathan L Finlay, Michael Prados, Sabine Mueller
{"title":"Marrow-ablative Consolidation Chemotherapy and Molecular Targeted Therapy Delivered in a Risk-adapted Manner for Newly Diagnosed Children with Choroid Plexus Carcinoma: A Work in Progress","authors":"Maxim Yankelevich, W. Zaky, L. Lafay-Cousin, Diana Osorio, Jenny K Adamski, U. Kordes, Jonathan L Finlay, Michael Prados, Sabine Mueller","doi":"10.1093/noajnl/vdae109","DOIUrl":null,"url":null,"abstract":"\n Choroid plexus carcinomas (CPC) are early childhood cancers characterized by loss of TP53 function and poor survival. We are analyzing data on TP53 status, survival and second cancers from the largest cohort of CPC receiving chemotherapy followed by consolidation with marrow-ablative chemotherapy (HDCx). Additionally, we discuss the rationale for targeted therapies for CPC patients. Currently, eight of 13 with Li-Fraumeni Syndrome (LFS)-associated CPC were treated and continued CPC-free, indicating that HDCx improves CPC-free survival in young children with TP53-mutated CPC. These data justify the inclusion of HDCx in the planned prospective international trial for children with TP53-mutated CPC.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":" 11","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae109","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Choroid plexus carcinomas (CPC) are early childhood cancers characterized by loss of TP53 function and poor survival. We are analyzing data on TP53 status, survival and second cancers from the largest cohort of CPC receiving chemotherapy followed by consolidation with marrow-ablative chemotherapy (HDCx). Additionally, we discuss the rationale for targeted therapies for CPC patients. Currently, eight of 13 with Li-Fraumeni Syndrome (LFS)-associated CPC were treated and continued CPC-free, indicating that HDCx improves CPC-free survival in young children with TP53-mutated CPC. These data justify the inclusion of HDCx in the planned prospective international trial for children with TP53-mutated CPC.
期刊介绍：
ACS Applied Electronic Materials is an interdisciplinary journal publishing original research covering all aspects of electronic materials. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials science, engineering, optics, physics, and chemistry into important applications of electronic materials. Sample research topics that span the journal's scope are inorganic, organic, ionic and polymeric materials with properties that include conducting, semiconducting, superconducting, insulating, dielectric, magnetic, optoelectronic, piezoelectric, ferroelectric and thermoelectric.
Indexed/Abstracted：
Web of Science SCIE
Scopus
CAS
INSPEC
Portico
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
